Tag: source

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 26. juni 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte NK-celler (TCR-NK) for behandling av solide kreftformer, kunngjør i dag at den NSGO-CTU sponsede fase II DOVACC kliniske studie (NCT04742075) som testet Ultimovacs' UV1 kreftvaksine ikke oppnådde sitt primære endepunkt om å forbedre progresjonsfri overlevelse (PFS). UV1 ble overtatt gjennom virksomhetssammenslåingen mellom de to selskapene i 2025. Dette avslutter den tidligere kommuniserte avviklingsfasen av UV1-kreftvaksine-programmet, og Zelluna anser nå programmet som avsluttet.

Oslo, 26 June 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO-CTU sponsored Phase II DOVACC clinical trial (NCT04742075) investigating the Ultimovacs UV1 cancer vaccine, inherited through the business combination between the two companies in 2025, did not meet the primary endpoint. This concludes the previously communicated wrap-up phase of the UV1 cancer vaccine programme and Zelluna now considers the programme closed.

PARIS, June 26, 2026 (GLOBE NEWSWIRE) -- La Federación Internacional del Automóvil (FIA), organismo rector del automovilismo deportivo a nivel mundial y Federación de Entidades de Movilidad en todo el mundo, ha presentado hoy sus mejores resultados económicos en 10 años.

The Official Hard Seltzer of U.S. Soccer is offering what’s believed to be the largest single fan prize ever tied to American soccer, paying one believer $5 million if the U.S. Men’s National Team wins it all

Completion of all stages brings the total strategic transaction to approximately $7 million and deepens the companies’ RF technology collaboration across defense, homeland security and critical infrastructure markets

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.